83
Participants
Start Date
August 27, 2018
Primary Completion Date
September 10, 2025
Study Completion Date
September 10, 2025
INCB081776
INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.
INCMGA00012
INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks
Memorial Sloan Kettering Cancer Center, New York
University of Pittsburgh, Pittsburgh
University of Pennsylvania Abramson Cancer Center, Philadelphia
Skane University Hospital Lund, Lund
Sarah Cannon Research Institute, Nashville
University of Wisconsin Carbone Cancer Center, Madison
Md Anderson Cancer Center, Houston
Yale Cancer Center, New Haven
Dana Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
Rigshospitalet Uni of Hospital of Copenhagen, Copenhagen
Odense University Hospital, Odense C
Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam
University Medical Center Groningen, Groningen
Erasmus Medical Center, Rotterdam
Haukeland University Hospital, Bergen
Utprøvingsenheten, Oslo University Hospital Radiumhospitalet, Oslo
Karolinska University Hospital Solna, Stockholm
Lead Sponsor
Incyte Corporation
INDUSTRY